References
- A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.
- Campbell LJ. Cytogenetics of lymphomas. Pathology 2005;37: 493–507.
- Nogai H, Dorken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 2011;29:1803–1811.
- Dave BJ, Nelson M, Sanger WG. Lymphoma cytogenetics. Clin Lab Med 2011;31:725–761.
- Dave BJ, Hess MM, Pickering DL, et al. Rearrangements of chromosome band 1p36 in non-Hodgkin's lymphoma. Clin Cancer Res 1999;5:1401–1409.
- Cheung KJ, Shah SP, Steidl C, et al. Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. Blood 2009;113:137–148.
- Dominguez G, Garcia JM, Pena C, et al. DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol 2006;24:805–815.
- Collavin L, Lunardi A, Del SG. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010;17:901–911.
- Bailey SG, Cragg MS, Townsend PA. Family friction as DeltaNp73 antagonises p73 and p53. Int J Biochem Cell Biol 2011;43:482–486.
- Stoffel A, Filippa D, Rao PH. The p73 locus is commonly deleted in non-Hodgkin's lymphomas. Leuk Res 2004;28:1341–1345.
- Stiewe T, Putzer BM. Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ 2002;9:237–245.
- Tannapfel A, Wasner M, Krause K, et al. Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma. J Natl Cancer Inst 1999;91:1154–1158.
- ISCN 2013: An International System for Human Cytogenetic Nomenclature. Shaffer LG, McGowan-Jordan J, and Schmid M (eds). Basel: S. Karger, 2013.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402–408.
- Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008;68:2551–2556.
- Cheung KJ, Johnson NA, Affleck JG, et al. Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. Cancer Res 2010;70:9166–9174.
- Cuadros M, Ribas G, Fernandez V, et al. Allelic expression and quantitative RT-PCR study of TAp73 and DeltaNp73 in non-Hodgkin's lymphomas. Leuk Res 2006;30:170–177.
- Duhoux FP, Ameye G, Lambot V, et al. Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies. PLoS One 2011;6:e26311.
- Sayan BS, Yang AL, Conforti F, et al. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci USA 2010;107:12877–12882.
- Conforti F, Sayan AE, Sreekumar R, et al. Regulation of p73 activity by post-translational modifications. Cell Death Dis 2012; 3:e285.
- Schaffel R, Hedvat CV, Teruya-Feldstein J, et al. Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma. Ann Oncol 2010;21:133–139.
- Rabenhorst SH, Burini RC, Schmitt FC. Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material. Pathology 1996;28:12–16.
- Provencio M, Martin P, Garcia V, et al. Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. Leuk Lymphoma 2010;51:2021–2030.
- Brigati C, Banelli B, Casciano I, et al. Epigenetic mechanisms regulate DeltaNP73 promoter function in human tonsil B cells. Mol Immunol 2011;48:408–414.
- Zhang LN, Li JY, Xu W. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther 2013;20:1–7.
- Toh WH, Nam SY, Sabapathy K. An essential role for p73 in regulating mitotic cell death. Cell Death Differ 2010;17:787–800.
- Busuttil V, Droin N, McCormick L, et al. NF-kappaB inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2. Proc Natl Acad Sci USA 2010;107:18061–18066.
- Melino G, Bernassola F, Ranalli M, et al. p73 Induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. J Biol Chem 2004;279:8076–8083.
- Ming L, Sakaida T, Yue W, et al. Sp1 and p73 activate PUMA following serum starvation. Carcinogenesis 2008;29:1878–1884.
- Clybouw C, Fischer S, Auffredou MT, et al. Regulation of memory B-cell survival by the BH3-only protein Puma. Blood 2011;118: 4120–4128.
- Grande L, Bretones G, Rosa-Garrido M, et al. Transcription factors Sp1 and p73 control the expression of the proapoptotic protein NOXA in the response of testicular embryonal carcinoma cells to cisplatin. J Biol Chem 2012;287:26495–26505.
- Michalak EM, Jansen ES, Happo L, et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009;16:684–696.